到 2030 年干眼症治疗市场预测：按产品类型、治疗、给药、药物、诊断、药物类型、配销通路、最终用户和地区进行的全球分析

根据 Stratistics MRC 的数据，2023 年全球干眼症治疗市场规模将达到 51 亿美元，预计到 2030 年将达到 94 亿美元，预测期内复合年增长率为 9.1%。

干眼综合症，或称为色盲角结膜炎 (KCS) 的疾病，其特征是眼睛表面缺乏润滑或水分。干眼症是一种普遍存在的疾病，可以随时影响任何人。其他干眼症状包括畏光、疼痛或灼热感、眼睛疼痛、发红、眼睛疲劳、眼睛发痒和其他与眼睛相关的问题。流泪也是干燥的征兆，因为眼睛表面的干燥会过度刺激泪液中水分的产生。

根据领先的眼保健公司 Bausch & Lomb 的投资者介绍，估计美国有 3800 万人患有干眼症，但其中只有 1900 万人被诊断出来。

干眼症呈上升趋势

随着年龄的增长，这种慢性疾病对人们的影响有所不同。由于饮食不良、隐形眼镜使用增加、看萤幕时间增加以及LASIK手术增加等因素，干眼症在年轻人和老年人群中的患病率都在增加。这就是结果。随着干眼症盛行率的上升，对该疾病采取更强化治疗性介入的需求将会增加，并可能推动干眼症市场在预测期内的扩张。

眼睛健康不被重视

人们很少定期去看眼科医生，除非他们有严重的临床问题。干眼症状，例如发红和灼热感，常常未被诊断出来。因此，可以使用这些处方药物治疗的患者越来越少。因此，这些眼部护理产品的接受度正在下降，市场拓展潜力有限。

增加研发活动

由于建立高效治疗线的大量研发投资，干眼症治疗市场正在扩大。随着LASIK手术的增加，对干眼症治疗的需求不断增加。先进技术开发投资的增加和新兴市场数量的增加预计也将在预测期内推动市场成长。

缺乏意识

大众对眼睛健康知之甚少。干眼症的许多症状鲜为人知，但透过正确的诊断和药物治疗可以快速治癒或缓解。除非有重大临床问题，否则患者很少去看眼科。对于许多干眼症患者来说，发红、发炎和其他症状被忽视或误诊，减少了接受处方药物治疗的人数。这阻碍了市场的拓展。

COVID-19 的影响：

大流行期间进行的大量研究发现，干眼症状在康復后持续数週或数月。这是一种常见的眼病，导致这种疾病的盛行率增加。此外，随着COVID-19的出现，人们的工作和学习习惯逐渐从线下转移到线上，导致疾病的盛行率上升。另一方面，我们发现，疫情期间，非必要治疗性介入的咨询减少，对这些治疗的需求也减少。

预计环孢素部门在预测期内将是最大的

由于环孢素类药物的长期使用，预计环孢素细分市场在预测期内将成为最大的细分市场。研究表明，它有助于治疗干眼症的征兆和症状。据报导，环孢菌素可以减少 T 细胞增殖，这是一种导致该疾病的发炎反应。 Restasis 和 Cequa 是 FDA 核准的干眼治疗药物。

医院药房业务预计在预测期内复合年增长率最高

由于对干眼诊断和治疗的设备和药物的需求不断增加，医院药学产业预计在预测期内将出现最高的复合年增长率。医院药剂师经常治疗需要专科治疗的严重或复杂干眼症患者。这些患者可能会受益于服用处方药，例如免疫调节剂和发炎药，这些药物通常在医院药房出售。

占比最大的地区：

预计北美在预测期内将占据最大的市场占有率。这种高市场占有率可归因于多种因素，包括重要行业参与企业的出现、干眼患者数量的增加以及老年人口的扩大。由于高龄化、数位设备的广泛普及和环境因素等多种因素，该地区干眼症的盛行率相对较高。

复合年增长率最高的地区：

由于整体医疗基础设施的改善、干眼患者病率的上升以及医疗保健可及性的改善，预计亚太地区在预测期内将保持最高的复合年增长率。在中国和印度等人口大国，心血管疾病的盛行率很高，市场参与企业不断增加的策略和趋势，如产品开拓、产品核可、联盟、合作和协议，正在推动该地区的扩张。我支持你。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

• 公司简介
  • 其他市场参与企业的综合分析（最多 3 家公司）
  • 主要企业SWOT分析（最多3家企业）
• 区域分割
  • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
• 竞争基准化分析
  • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

• 概述
• 利害关係人
• 调查范围
• 调查方法
  • 资料探勘
  • 资料分析
  • 资料检验
  • 研究途径
• 调查来源
  • 主要调查来源
  • 二次调查来源
  • 先决条件

第3章市场趋势分析

• 介绍
• 促进因素
• 抑制因素
• 机会
• 威胁
• 产品分析
• 最终用户分析
• 新兴市场
• 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

• 供应商的议价能力
• 买方议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第5章全球干眼症治疗市场：依产品类型

• 介绍
• 人工泪液
• 环孢素
• 润滑剂
• 皮质类固醇
• 准时袋
• 欧米茄补充剂
• 其他产品类型

第6章全球干眼症治疗市场：依治疗分类

• 介绍
• 发炎
• 胆碱能促效剂
• 感染疾病
• 润滑剂
• 抗过敏药
• 其他治疗方法

第7章全球干眼症治疗市场：按给药

• 介绍
• 多剂量
• 单一给药

第8章全球干眼症治疗市场：依药物分类

• 介绍
• 西德拉
• 恢復
• 塞夸
• 艾斯维斯
• 蒂亚
• 其他药品

第9章全球干眼症治疗市场：依诊断

• 介绍
• 泪液渗透压测试
• 席默试验
• 综合眼科检查

第10章全球干眼症治疗市场：依药物类型

• 介绍
• 成药(OTC)
• 处方笺(Rx) 药物
• 其他的

第11章全球干眼症治疗市场：按配销通路

• 介绍
• 医院药房
• 零售药房
• 线上药房

第12章全球干眼症治疗市场：依最终用户分类

• 介绍
• 居家医疗
• 医院
• 专科诊所
• 其他最终用户

第13章全球干眼症治疗市场：按地区

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 纽西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 卡达
  • 南非
  • 中东和非洲其他地区

第14章进展

• 合约、伙伴关係、协作和合资企业
• 收购和合併
• 新产品发布
• 业务扩展
• 其他关键策略

第15章公司简介

• Novartis AG
• Eli Lilly and Company
• AbbVie, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Sanofi
• Santen Pharmaceutical Co., Ltd.
• Pfizer Inc.
• AFT Pharmaceuticals
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Akorn Operating Company LLC
• Bausch+Lomb Corporation
• Allergan
• OASIS Medical
• GlaxoSmithKline plc
• Oyster Point Pharma, Inc.
• Otsuka America Pharmaceutical, Inc.
• Novaliq GmbH
• F. Hoffmann-La Roche Ltd.

According to Stratistics MRC, the Global Dry Eye Syndrome Market is accounted for $5.1 billion in 2023 and is expected to reach $9.4 billion by 2030 growing at a CAGR of 9.1% during the forecast period. The disease known as dry eye syndrome, or keratoconjunctivitis sicca (KCS), is characterized by a lack of lubrication or moisture on the eye's surface. It is a widespread condition that can affect anyone at any time. Other dry eye symptoms include photophobia, aching and burning feelings, hurting eyes, red eyes, fatigued eyes, itchy eyes, and other eye-related issues. Watery eyes can also be a sign because the dryness of the eye's surface over-stimulates the creation of the watery component of tears.

According to investor presentation of Bausch + Lomb, a leading eye care company, in U.S. an estimated 38 million people affected with dry eye disease (DED) out of which only 19 million were diagnosed.

Market Dynamics:

Driver:

Growing prevalence of dry eye syndrome

This chronic illness affects people differently as they age. The prevalence is rising in both the young and the elderly population, though, as a result of bad food, increased use of contact lenses, more screen time, and an increase in LASIK procedures. The need for more potent treatment interventions for this illness will rise as its prevalence rises, fueling the expansion of the dry eye syndrome market throughout the projected period.

Restraint:

Low priority given to eye health

Unless there is a severe clinical problem, people seldom consult ophthalmologists on a regular basis. It happens frequently that dry eye symptoms like redness, burning, and other similar ones go undiagnosed. The number of patients who can be treated with these prescription medications as a result of this has decreased. The market expansion potential is therefore limited as a result of the lower acceptance rate of these eye care products.

Opportunity:

Increase in the number of R & D activities

The market for treating dry eye problems is expanding as a consequence of the high R&D investment on the creation of efficient treatment lines. As the country performs more LASIK surgeries, there is a growing demand for treatments for dry eye syndrome. Rising investments in the development of advanced technologies and an increase in the number of emerging markets will also help the market grow during the forecast period.

Threat:

Lack of awareness

The general public knows virtually little about eye health. Many of the symptoms of dry eyes, which may be swiftly cured or relieved with a correct diagnosis and medications, are not well known. Patients rarely visit ophthalmologists unless there is a major clinical problem. Many dry eye sufferers have their redness, irritation, and other symptoms ignored or misdiagnosed, which reduces the number of individuals who may receive prescription pharmaceutical treatment. This is limiting the market from expanding.

COVID-19 Impact:

Numerous investigations conducted during the pandemic discovered that individuals continued to experience dry eye symptoms for several weeks or months after they had recovered. As this is a prevalent ophthalmic disorder, this resulted in a rise in the prevalence of this ailment. Additionally, during the COVID-19, a gradual transition in people's work and study habits from offline to online led to a rise in the prevalence of this disorder. On the other hand, it was discovered that throughout the pandemic, consultations for all non-essential therapeutic interventions had decreased, which led to a fall in the demand for these therapies.

The cyclosporine segment is expected to be the largest during the forecast period

The cyclosporine segment is expected to be the largest during the forecast period owing to the long-standing use of medications using cyclosporine as a basis. Research has shown its usefulness for treating the signs and symptoms of dry eye illness. Cyclosporine has been reported to decrease T-cell proliferation, an inflammatory response that contributes to disease. Restasis and Cequa are two drugs for treating the symptoms of dry eye that have FDA approval.

The hospital pharmacy segment is expected to have the highest CAGR during the forecast period

The hospital pharmacy segment is expected to have the highest CAGR during the forecast period owing to increasing demand for devices and drugs for the diagnosis and treatment of dry eye disease. Patients with more severe or complicated instances of dry eye disease who needs specialist care are frequently catered to by hospital pharmacists. These patients may benefit from taking prescription drugs like Immunomodulators or anti-inflammatory drugs, which are commonly sold at hospital pharmacies.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. This high market share may be ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from dry eye disease, an expanding elderly population, among others. This region has a relatively high prevalence of dry eye disease, driven by various factors such as an aging population, widespread use of digital devices, and environmental factors.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to improvements in overall healthcare infrastructure, rising prevalence of dry eye disease, and improved access to healthcare. The high prevalence of cardiovascular diseases in countries with high populations, such as China and India, as well as the rising number of market players' strategies and trends, such as product development, product approval, partnership, collaboration, and agreement, are driving the region to expand.

Key players in the market

Some of the key players in Dry Eye Syndrome market include: Novartis AG, Eli Lilly and Company, AbbVie, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi, Santen Pharmaceutical Co., Ltd., Pfizer Inc ., AFT Pharmaceuticals, Merck & Co., Inc. , Johnson & Johnson Services, Inc., Akorn Operating Company LLC , Bausch + Lomb Corporation, Allergan, OASIS Medical, GlaxoSmithKline plc, Oyster Point Pharma, Inc., Otsuka America Pharmaceutical, Inc., Novaliq GmbH and F. Hoffmann-La Roche Ltd.

Key Developments:

In June 2023, Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.

In May 2023, Bausch + Lomb Corporation and Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved MIEBO (perfluorohexyloctane ophthalmic solution; formerly known as NOV03), for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only FDA-approved treatment for DED that directly targets tear evaporation.

Product Types Covered:

• Artificial Tears
• Cyclosporine
• Lubricants
• Corticosteroids
• Punctual Bags
• Omega Supplements
• Other Product Types

Treatments Covered:

• Anti-Inflammatory
• Cholinergics
• Anti-Infectives
• Lubricating Agent
• Anti-Allergics
• Other Treatments

Doses Covered:

• Multi Dose
• Unit Dose

Drugs Covered:

• Xiidra
• Restasis
• Cequa
• Eysuvis
• Tyrvaya
• Other Drugs

Diagnosis Covered:

• Tear Osmolarity Test
• Schirmer Test
• Comprehensive Eye Exam

Medication Types Covered:

• Over the counter (OTC) Drug
• Prescription (Rx) Drug
• Other Medication Types

Distribution Channels Covered:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

End Users Covered:

• Homecare
• Hospitals
• Specialty Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Dry Eye Syndrome Treatment Market, By Product Type

• 5.1 Introduction
• 5.2 Artificial Tears
• 5.3 Cyclosporine
• 5.4 Lubricants
• 5.5 Corticosteroids
• 5.6 Punctual Bags
• 5.7 Omega Supplements
• 5.8 Other Product Types

6 Global Dry Eye Syndrome Treatment Market, By Treatment

• 6.1 Introduction
• 6.2 Anti-Inflammatory
• 6.3 Cholinergics
• 6.4 Anti-Infectives
• 6.5 Lubricating Agent
• 6.6 Anti-Allergics
• 6.7 Other Treatments

7 Global Dry Eye Syndrome Treatment Market, By Dose

• 7.1 Introduction
• 7.2 Multi Dose
• 7.3 Unit Dose

8 Global Dry Eye Syndrome Treatment Market, By Drug

• 8.1 Introduction
• 8.2 Xiidra
• 8.3 Restasis
• 8.4 Cequa
• 8.5 Eysuvis
• 8.6 Tyrvaya
• 8.7 Other Drugs

9 Global Dry Eye Syndrome Treatment Market, By Diagnosis

• 9.1 Introduction
• 9.2 Tear Osmolarity Test
• 9.3 Schirmer Test
• 9.4 Comprehensive Eye Exam

10 Global Dry Eye Syndrome Treatment Market, By Medication Type

• 10.1 Introduction
• 10.2 Over the counter (OTC) Drug
• 10.3 Prescription (Rx) Drug
• 10.4 Other Medication Types

11 Global Dry Eye Syndrome Treatment Market, By Distribution Channel

• 11.1 Introduction
• 11.2 Hospital Pharmacy
• 11.3 Retail Pharmacy
• 11.4 Online Pharmacy

12 Global Dry Eye Syndrome Treatment Market, By End User

• 12.1 Introduction
• 12.2 Homecare
• 12.3 Hospitals
• 12.4 Specialty Clinics
• 12.5 Other End Users

13 Global Dry Eye Syndrome Treatment Market, By Geography

• 13.1 Introduction
• 13.2 North America
  • 13.2.1 US
  • 13.2.2 Canada
  • 13.2.3 Mexico
• 13.3 Europe
  • 13.3.1 Germany
  • 13.3.2 UK
  • 13.3.3 Italy
  • 13.3.4 France
  • 13.3.5 Spain
  • 13.3.6 Rest of Europe
• 13.4 Asia Pacific
  • 13.4.1 Japan
  • 13.4.2 China
  • 13.4.3 India
  • 13.4.4 Australia
  • 13.4.5 New Zealand
  • 13.4.6 South Korea
  • 13.4.7 Rest of Asia Pacific
• 13.5 South America
  • 13.5.1 Argentina
  • 13.5.2 Brazil
  • 13.5.3 Chile
  • 13.5.4 Rest of South America
• 13.6 Middle East & Africa
  • 13.6.1 Saudi Arabia
  • 13.6.2 UAE
  • 13.6.3 Qatar
  • 13.6.4 South Africa
  • 13.6.5 Rest of Middle East & Africa

14 Key Developments

• 14.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 14.2 Acquisitions & Mergers
• 14.3 New Product Launch
• 14.4 Expansions
• 14.5 Other Key Strategies

15 Company Profiling

• 15.1 Novartis AG
• 15.2 Eli Lilly and Company
• 15.3 AbbVie, Inc.
• 15.4 Teva Pharmaceutical Industries Ltd.
• 15.5 Sun Pharmaceutical Industries Ltd.
• 15.6 Sanofi
• 15.7 Santen Pharmaceutical Co., Ltd.
• 15.8 Pfizer Inc.
• 15.9 AFT Pharmaceuticals
• 15.10 Merck & Co., Inc.
• 15.11 Johnson & Johnson Services, Inc.
• 15.12 Akorn Operating Company LLC
• 15.13 Bausch + Lomb Corporation
• 15.14 Allergan
• 15.15 OASIS Medical
• 15.16 GlaxoSmithKline plc
• 15.17 Oyster Point Pharma, Inc.
• 15.18 Otsuka America Pharmaceutical, Inc.
• 15.19 Novaliq GmbH
• 15.20 F. Hoffmann-La Roche Ltd.

List of Tables

• Table 1 Global Dry Eye Syndrome Treatment Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Dry Eye Syndrome Treatment Market Outlook, By Product Type (2021-2030) ($MN)
• Table 3 Global Dry Eye Syndrome Treatment Market Outlook, By Artificial Tears (2021-2030) ($MN)
• Table 4 Global Dry Eye Syndrome Treatment Market Outlook, By Cyclosporine (2021-2030) ($MN)
• Table 5 Global Dry Eye Syndrome Treatment Market Outlook, By Lubricants (2021-2030) ($MN)
• Table 6 Global Dry Eye Syndrome Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 7 Global Dry Eye Syndrome Treatment Market Outlook, By Punctual Bags (2021-2030) ($MN)
• Table 8 Global Dry Eye Syndrome Treatment Market Outlook, By Omega Supplements (2021-2030) ($MN)
• Table 9 Global Dry Eye Syndrome Treatment Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 10 Global Dry Eye Syndrome Treatment Market Outlook, By Treatment (2021-2030) ($MN)
• Table 11 Global Dry Eye Syndrome Treatment Market Outlook, By Anti-Inflammatory (2021-2030) ($MN)
• Table 12 Global Dry Eye Syndrome Treatment Market Outlook, By Cholinergics (2021-2030) ($MN)
• Table 13 Global Dry Eye Syndrome Treatment Market Outlook, By Anti-Infectives (2021-2030) ($MN)
• Table 14 Global Dry Eye Syndrome Treatment Market Outlook, By Lubricating Agent (2021-2030) ($MN)
• Table 15 Global Dry Eye Syndrome Treatment Market Outlook, By Anti-Allergics (2021-2030) ($MN)
• Table 16 Global Dry Eye Syndrome Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
• Table 17 Global Dry Eye Syndrome Treatment Market Outlook, By Dose (2021-2030) ($MN)
• Table 18 Global Dry Eye Syndrome Treatment Market Outlook, By Multi Dose (2021-2030) ($MN)
• Table 19 Global Dry Eye Syndrome Treatment Market Outlook, By Unit Dose (2021-2030) ($MN)
• Table 20 Global Dry Eye Syndrome Treatment Market Outlook, By Drug (2021-2030) ($MN)
• Table 21 Global Dry Eye Syndrome Treatment Market Outlook, By Xiidra (2021-2030) ($MN)
• Table 22 Global Dry Eye Syndrome Treatment Market Outlook, By Restasis (2021-2030) ($MN)
• Table 23 Global Dry Eye Syndrome Treatment Market Outlook, By Cequa (2021-2030) ($MN)
• Table 24 Global Dry Eye Syndrome Treatment Market Outlook, By Eysuvis (2021-2030) ($MN)
• Table 25 Global Dry Eye Syndrome Treatment Market Outlook, By Tyrvaya (2021-2030) ($MN)
• Table 26 Global Dry Eye Syndrome Treatment Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 27 Global Dry Eye Syndrome Treatment Market Outlook, By Diagnosis (2021-2030) ($MN)
• Table 28 Global Dry Eye Syndrome Treatment Market Outlook, By Tear Osmolarity Test (2021-2030) ($MN)
• Table 29 Global Dry Eye Syndrome Treatment Market Outlook, By Schirmer Test (2021-2030) ($MN)
• Table 30 Global Dry Eye Syndrome Treatment Market Outlook, By Comprehensive Eye Exam (2021-2030) ($MN)
• Table 31 Global Dry Eye Syndrome Treatment Market Outlook, By Medication Type (2021-2030) ($MN)
• Table 32 Global Dry Eye Syndrome Treatment Market Outlook, By Over the counter (OTC) Drug (2021-2030) ($MN)
• Table 33 Global Dry Eye Syndrome Treatment Market Outlook, By Prescription (Rx) Drug (2021-2030) ($MN)
• Table 34 Global Dry Eye Syndrome Treatment Market Outlook, By Other Medication Types (2021-2030) ($MN)
• Table 35 Global Dry Eye Syndrome Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 36 Global Dry Eye Syndrome Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 37 Global Dry Eye Syndrome Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 38 Global Dry Eye Syndrome Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 39 Global Dry Eye Syndrome Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 40 Global Dry Eye Syndrome Treatment Market Outlook, By Homecare (2021-2030) ($MN)
• Table 41 Global Dry Eye Syndrome Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 42 Global Dry Eye Syndrome Treatment Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 43 Global Dry Eye Syndrome Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.